Montelukast as a treatment modality for eosinophilic gastroenteritis

Acta Gastro-Enterologica Belgica

Volumn 74, Issue 4, 2011, Pages 570-575

  de Maeyer, Nikolaas ^a   Kochuyt, A M ^a   van Moerkercke, W ^a   Hiele, M ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Corticosteroids; Eosinophilic infiltrates; Gastrointestinal tract; Inflammation; Montelukast; Treatment

Indexed keywords

AZATHIOPRINE; CYTOKINE; LANSOPRAZOLE; LEUKOTRIENE D4; LEVOTHYROXINE; METHYLPREDNISOLONE; MONTELUKAST; OMEPRAZOLE; SULPIRIDE; ACETIC ACID DERIVATIVE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; QUINOLINE DERIVATIVE;

ADULT; AUTOIMMUNE DISEASE; CASE REPORT; CHOLECYSTECTOMY; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; DUODENUM BIOPSY; EOSINOPHILIA; EOSINOPHILIC GASTROENTERITIS; GASTROINTESTINAL REFLUX; HUMAN; HYPOTHYROIDISM; LEUKOCYTE COUNT; MAINTENANCE THERAPY; MALE; MEDICAL HISTORY; PANCREAS FUNCTION TEST; PANCREATITIS; RECURRENT DISEASE; REVIEW; SIDE EFFECT; STEROID THERAPY; STOMACH OBSTRUCTION; ARTICLE; GASTROENTERITIS;

ACETATES; ADULT; EOSINOPHILIA; GASTROENTERITIS; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; QUINOLINES;

EID: 84858036048     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. KAIJSER R. Allergic disease of the gut from the point of view of the surgeon. Arch. Klin. Chir., 1937, 188: 36-64.
2. van MOERKERCKE W., de WULF D., DEBOEVER G. Eosinofiele gastro-enteritis in de differentiaaldiagnostiek bij persisterende gastrointestinale symptomen. Tijdschr. Geneesk., 2010, 66: 71-78.
3. CHANG J., CHOUNG R., LEE R.U. et al. A shift in the clinical spectrum of eosinophilic gastroenteritis toward the mucosal disease type. Clin. Gastro-enterol. Hepatol., 2010, 8: 669-675.
4. TALLEY N., SHORTER R., PHILIPS S., ZINSMEISTER A. Eosinophilic gastroenteritis: a clinicopathological study of patients with disease of the mucosa, muscle layer, and subserosal tissues. Gut, 1990, 31: 54-58.
5. YAN B., SHAFFER E. Primary eosinophilic disorders of the gastrointestinal tract. Gut, 2009, 58: 721-732.
6. CHEN M.-J., CHU C.-H., LIN S.-C., SHIH S.-C., WANG T.-E. Eosinophilic gastroenteritis: clinical experience with 15 patients. World J. Gastroenterol., 2003, 9: 2813-2816.
7. OH H.E., CHETTY R. Eosinophilic gastroenteritis: a review. J. Gastro-enterol., 2008, 43: 741-750.
8. KLEIN N., HARGROVE R., SLEISENGER M., JEFFRIES G. Eosinophilic gastroenteritis. Medicine (Baltimore), 1970, 49: 299-319.
9. MIYAMASU M., MISAKI Y., IZUMI S. et al. Glucocorticoids inhibit chemo kine generation by human eosinophils. J. Allergy Clin. Immunol., 1998, 101: 75-83.
10. KOKKONEN J., RUNSKA T., KARTTUNEN T.J., NIINIMÄKI A. Mucosal pathology of the foregut associated with food allergy and recurrent abdominal pain in children. Acta Paediatr., 2001, 90: 16-21.
11. BISSCHOFF S. Food allergy and eosinophilic gastroenteritis and colitis. Curr. Opin. Allergy Clin. Immunol., 2010, 10: 238-245.
12. CHEHAde M., SICHERER S.H., MAGID M.S. et al. Multiple exudative ulcers and pseudopolyps in allergic eosinophilic gastroenteritis that responded to dietary therapy. J. Pediatr. Gastroenterol. Nutr., 2007, 45: 354-357.
13. JUSTINICH C., KATZ A., GURBINDO C. et al. Elemental diet improves steroid-dependent eosinophilic gastroenteritis and reverses growth failure. J. Pediatr. Gastroenterol. Nutr., 1996, 23: 81-85.
14. GARRETT J.K., JAMESON S.C., THOMSON B. et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J. Allergy Clin. Immunol., 2004, 113: 115-160.
15. STEIN M.L., COLLINS M.H., VILLANUEVA J.M. et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J. Allergy Clin. Immunol., 2006, 118: 1312-9.
16. SIMON D., BRAATHEN L., SIMON H.-U. Anti-interleukin antibody therapy in eosinophilic diseases. Pathobiology, 2005, 72: 287-292.
17. FOROUGHI S., FOSTER B., KIM N. et al. Anti-IgE treatment of eosinophil associated gastrointestinal disorders. J. Allergy Clin. Immunol., 2007, 120: 594-601.
18. STONE K., PRUSSIN C. Immunomodulatory therapy of eosinophilassociated gastrointestinal diseases. Clin. Exp. Allergy, 2008, 38: 1858-1865.
19. SHIRAI T., HASHIMOTO D., SUZUKI K. et al. Succesful treatment of eosinophilic gastroenteritis with suplatast tosilate. J. Allergy Clin. Immunol., 2001, 107: 924.
20. SHARIAR M., MIZUGUCHI H., MAEYAMA K. et al. Suplatast tosilate inhibits histamine signalling by direct and indirect down-regulation of histamine H1 receptor gene expression through suppression of histidine decarboxylase and IL-4 gene transcriptions. J. Immunol., 2009, 183: 2133-2141.
21. SANO Y., YAMADA H. Progress in suplatast tosilate research. Clin. Exp. Allergy, 2007, 37: 970-972.
22. AGRAWAL D. CHENG G., KIM M.-J., KINIWA M. Interaction of suplatast tosilate (IPD) with chloride channels in human blood eosinophils: a potential mechanism underlying its anti-allergic and anti-asthmatic effects. Clin. Exp. Allergy, 2008, 38: 305-312.
23. DI GIOACCHINO M., PIZZICANNELLA G., FINI N. et al. Sodium cromoglycate in the treatment of eosinophilic gastroenteritis. Allergy, 1990, 45: 161-166.
24. PEREZ-MILLAN A., LARTIN-LORENTE J.L., LOPEZ-MORATE A. et al. Subserosal eosinophilic gastroenteritis treated efficaciously with sodium cromoglycate. Dig. Dis. Sci., 1997, 42: 342-344.
25. COPELAND B., ARAMIde O., WEHBE S., FITZGERALD S., KRISHNASWAMY G. Eosinophilia in a patient with cyclical vomiting: a case report. Clin. Mol. Allergy, 2004, 2: 7.
26. NETZER P., GSCHOSSMANN J., STRAUMANN A., SENDENSKY A., WEIMANN R., SCOEPFER A. Corticosteroid-dependent eosinophilic oeso-phagitis: azathioprine and 6-mercaptopurine can induce and maintain longterm remission. Eur. J. Gastroenterol. Hepatol., 2007, 19: 865-869.
27. BOLUKBAS F.F., BOLUKBAS C., UZUNKOY A. et al. A dramatic response to ketotifen in a case of eosinophilic gastroenteritis mimicking abdominal emergency. Dig. Dis. Sci., 2004, 49: 1782-1785.
28. MELAMED I., FEANNY S.J., SHERMAN P.M., ROIFMAN C.M. Benefit of ketotifen in patients with eosinophilic gastroenteritis. Am. J. Med., 199, 90: 310-314.
29. GURISH M.F., HUMBLES A., TAO H. et al. CCR3 is required for tissue eosinophilia and larval cytotoxicity after infection with Trichinella Spiralis. J. Immunol., 2002, 168: 5730-5736.
30. BOCHNER B. Verdict in the case of therapies versus eosinophils: the jury is still out. J. Allergy Clin. Immunol., 2004, 113: 3-9.
31. DING C., LI J., ZHANG X. Bertilimumab Cambrige Antibody Technology Group. Curr. Opin. Investig. Drugs, 2004, 5: 1213-8.
32. SPADA C., NIEVES A., KRAUSS A.-P., WOODWARD D. Comparison of leukotriene B4 and D4 effect in human eosinophil and neutrophil motility in vitro. J. Leukoc. Biol., 1994, 55: 183-191.
33. FRIESEN C., KEARNS G., ANDRE L., NEUSTROM M., ROBERTS C., ABDEL-RAHMAN S. Clinical efficacy and pharmacokinetics of montelu-kast in dyspeptic children with duodenal eosinophilia. J. Pediatric Gastro-enterol. Nutr., 2004, 38: 343-351.
34. FRIESEN C., NEILAN N., SCHURMAN J., TAYLOR D., KEARNS G., ABDEL-RAHMAN S. Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: effect on eosinophil density and activation in relation to pharmacokinetics. BMC Gastroenterology, 2009, 9: 32.
35. DAIKH B., RYAN C., SCHWARTZ R. Montelukast reduces peripheral blood eosinophilia but not tissue eosinophilia or symptoms in a patient with eosinophilic gastroenteritis and esophageal stricture. Ann. Allergy Asthma Immunol., 2003, 90: 23-27.
36. UREK M.C., KUJUNDZIC M., BANIC M., UREK R., VEIC T., KARDUM D. Gut, 2006, 55: 1363-1364.
37. QUACK I., SELLIN L., BUCHNER N., THEEGARTEN D., RUMP L., HENNING B. Eosinophilic gastroenteritis in a young girl-long term remission under montelukast. BMC gastroenterol., 2005, 5: 24.
38. SCHWARTZ D., PARDI D., MURRAY J. Use of montelukast as steroidsparing agent for recurrent eosinophilic gastroenteritis. Dig. Dis. Sci., 2001, 46: 1787-1790.
39. NEUSTROM M., FRIESEN C. Treatment of eosinophilic gastroenteritis with montelukast. J. Allergy Clin. Immunol., 1999, 104: 506.
40. VANDERHOOF J., YOUNG R., HANNER T., KETTLEHUT B. Montelukast: use in pediatric patients with eosinophilic gastrointestinal disease. J. Pediatr. gastro enterol. Nutr., 2003, 36: 293-294.
41. TALLEY N.J., KEPHART G.M., MCGOVERN T.W., CARPENTER H.A., GLEICH G.J. Deposition of eosinophil granule major basic protein in eosinophilic gastro enteritis and celiac disease. Gastroenterology, 1992, 103: 137-145.
42. LOWICHIK A., WEINBERG A.G. A quantitative evaluation of mucosal eosinophils in the pediatric gastro-intestinal tract. Mod. Path., 1996, 9: 110-114.
43. WOSZCZEK G., CHEN L., ALSAATY S., NAGINENI S., SHELHAMER J. Concentration-dependent noncysteinyl leukotriene type 1 receptor-mediated inhibitory activity of leukotriene receptor antogonists. J. Immunol., 2010, 184: 2219-2225.
44. PRICE D. Tolerability of montelukast. Drugs, 2000, 59 Suppl: 35-45.
45. LIPWORTH B. Leukotriene-receptor antagonists. Lancet, 1999, 353: 57-62.
46. BISGAARD H., SKONER D., BOZA M. et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr. Pulmonol., 2009, 44: 568-579.
47. Leukotrieen inhibitors: montelukast (marketed as Singulair), zafirlukast (marketed as Accolate) and zileuton (marketed as Zyflo and Zyflo CR). Healthcare Professional Sheet. Washington (DC): US Food and Drug Administration, 2009.
48. WALLERSTEDT S., BRÜNLOF G., SUNDSTRÖM A., ERIKSSON A. Montelukast and psychiatric disorders in children. Pharmacoepidemiol. Drug Saf., 2009; 18: 858-864.
49. PHILIP G., HUSTAD C., NOONAN G. et al. Reports of suidicality in clinical trials of montelukast. J. Allergy Clin. Immunol., 2009, 124: 691-696.
50. PHILIP G., HUSTAD C.M., MALICE M.-P. et al. Analysis of behaviorrelated adverse experiences in clinical trials of montelukast. J. Allergy Clin. Immunol., 2009, 124: 699-706.
51. MANALAI., WOO J.M., POSTOLACHE T.T. Suicidality and montelukast. Expert Opin Drug Saf., 2009, 8: 273-82.
52. HOLBROOK J., HARIK-KHAN R. Montelukast and emotional well-being as a marker for depression: results from 3 randomized, double-masked clinical trials. J. Allergy Clin. Immunol., 2008, 122: 828-829.
53. KELSAY K. Assessing risk: data from montelukast clinical trials. J. Allergy Clin. Immunol., 2009, 124: 697-8.
54. TUGGEY J.M., HOSKER H.S. Churg-Strauss syndrome associated with montelukast therapy. Thorax, 2000, 55: 805-806.
55. HAUSER T., MAHR A., METZLER C. et al. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a casecrossover study. Thorax, 2008, 63: 677-682.
56. JENNINGS L., HO W., GULMANN C., MURPHY M. Churg-Strauss syndrome secondary to antileucotriene therapy in a patient not receiving oral corticosteroids. Clin. Exp. Dermatol., 2009, 34: e430-e431.
57. GERARD A., HARKISOON S. Singulair-induced anaphylaxis ? J. Fam. Practice, 2009, 58: 133-134.